{"id":674896,"date":"2023-11-02T10:12:02","date_gmt":"2023-11-02T10:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=674896"},"modified":"2023-11-02T10:12:02","modified_gmt":"2023-11-02T10:12:02","slug":"parkinson-disease-pipelineclinical-trials-during-the-forecast-period-20232032-key-companies-novide-biopharmaceuticals-roche-pharmaceuticals-centogene-gmbh","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinson-disease-pipelineclinical-trials-during-the-forecast-period-20232032-key-companies-novide-biopharmaceuticals-roche-pharmaceuticals-centogene-gmbh_674896.html","title":{"rendered":"Parkinson Disease Pipeline|Clinical trials During the Forecast Period (2023-2032)| Key Companies &#8211; Novide Biopharmaceuticals, Roche Pharmaceuticals, Centogene GmbH"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Parkinson Disease Pipeline|Clinical trials During the Forecast Period (2023-2032)| Key Companies - Novide Biopharmaceuticals, Roche Pharmaceuticals, Centogene GmbH\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Parkinson Disease Pipeline|Clinical trials During the Forecast Period (2023-2032)| Key Companies - Novide Biopharmaceuticals, Roche Pharmaceuticals, Centogene GmbH\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Parkinson&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlays comprehensive insights into present clinical development scenario and growth prospects across the Parkinson&#8217;s Disease market. A detailed picture of the Parkinson&#8217;s Disease pipeline landscape is provided, which includes the disease overview and Parkinson&#8217;s Disease treatment guidelines.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Parkinson&#8217;s Disease Pipeline Insights, 2023<\/a>&#8221; report by DelveInsight outlays comprehensive insights into present clinical development scenario and growth prospects across the Parkinson&#8217;s Disease market. A detailed picture of the Parkinson&#8217;s Disease pipeline landscape is provided, which includes the disease overview and Parkinson&#8217;s Disease treatment guidelines.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Key Highlights Parkinson&#8217;s Disease&nbsp; Market&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Companies working in the Chronic Pruritus market are Novide Biopharmaceuticals, Roche Pharmaceuticals, Centogene GmbH<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Therapies in Chronic Pruritus are &nbsp;Prasinezumab, NAV5001,&nbsp; L-DOPA, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Parkinson Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Parkinson&rsquo;s disease is a brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. Symptoms usually begin gradually and worsen over time. As the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/ec1d66afb62b9a550f13e8583bfcaa46.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Click here to learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Parkinson&#8217;s Disease Market Landscape<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Report Covers the Parkinson&#8217;s Disease Epidemiology Segmented by:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Pruritus prevalent cases&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Pruritus incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Pruritus&nbsp; treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Pruritus diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Parkinson Disease Market Outlook&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Parkinson disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Parkinson Disease market trends by analyzing the impact of current Chronic Pruritus therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of Parkinson Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Pruritus market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Chronic Pruritus market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies Working in the&nbsp; Parkinson Disease&nbsp; Market<\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vyne Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Haisco Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Trevi Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sanofi&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;Parkinson Disease Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dupilumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pregabalin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nalbuphine HCl ER<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Chronic Pruritus Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Pruritus Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Executive Summary of Chronic Pruritus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Pruritus Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Chronic Pruritus Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Parkinson Disease Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=parkinson-disease-pipelineclinical-trials-during-the-forecast-period-20232032-key-companies-novide-biopharmaceuticals-roche-pharmaceuticals-centogene-gmbh\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=parkinson-disease-pipelineclinical-trials-during-the-forecast-period-20232032-key-companies-novide-biopharmaceuticals-roche-pharmaceuticals-centogene-gmbh\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP Parkinson&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlays comprehensive insights into present clinical development scenario and growth prospects across the Parkinson&#8217;s Disease market. A detailed picture of the Parkinson&#8217;s Disease pipeline landscape is provided, which &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/parkinson-disease-pipelineclinical-trials-during-the-forecast-period-20232032-key-companies-novide-biopharmaceuticals-roche-pharmaceuticals-centogene-gmbh_674896.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417],"tags":[],"class_list":["post-674896","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=674896"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674896\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=674896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=674896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=674896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}